These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

638 related items for PubMed ID: 26466871

  • 1. Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials.
    Lockley SW, Dressman MA, Licamele L, Xiao C, Fisher DM, Flynn-Evans EE, Hull JT, Torres R, Lavedan C, Polymeropoulos MH.
    Lancet; 2015 Oct 31; 386(10005):1754-64. PubMed ID: 26466871
    [Abstract] [Full Text] [Related]

  • 2. Tasimelteon for the treatment of non-24-hour sleep-wake disorder.
    Neubauer DN.
    Drugs Today (Barc); 2015 Jan 31; 51(1):29-35. PubMed ID: 25685859
    [Abstract] [Full Text] [Related]

  • 3. Tasimelteon: a melatonin receptor agonist for non-24-hour sleep-wake disorder.
    Johnsa JD, Neville MW.
    Ann Pharmacother; 2014 Dec 31; 48(12):1636-41. PubMed ID: 25204464
    [Abstract] [Full Text] [Related]

  • 4. Tasimelteon: A Review in Non-24-Hour Sleep-Wake Disorder in Totally Blind Individuals.
    Keating GM.
    CNS Drugs; 2016 May 31; 30(5):461-8. PubMed ID: 27003694
    [Abstract] [Full Text] [Related]

  • 5. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials.
    Rajaratnam SM, Polymeropoulos MH, Fisher DM, Roth T, Scott C, Birznieks G, Klerman EB.
    Lancet; 2009 Feb 07; 373(9662):482-91. PubMed ID: 19054552
    [Abstract] [Full Text] [Related]

  • 6. Tasimelteon for treating non-24-h sleep-wake rhythm disorder.
    Nishimon S, Nishimon M, Nishino S.
    Expert Opin Pharmacother; 2019 Jun 07; 20(9):1065-1073. PubMed ID: 30990759
    [Abstract] [Full Text] [Related]

  • 7. Mechanism of action of tasimelteon in non-24 sleep-wake syndrome: treatment for a circadian rhythm disorder in blind patients.
    Stahl SM.
    CNS Spectr; 2014 Dec 07; 19(6):475-8. PubMed ID: 25422900
    [Abstract] [Full Text] [Related]

  • 8. Diagnosis and Treatment of Non-24-h Sleep-Wake Disorder in the Blind.
    Emens JS, Eastman CI.
    Drugs; 2017 Apr 07; 77(6):637-650. PubMed ID: 28229310
    [Abstract] [Full Text] [Related]

  • 9. Tasimelteon (Hetlioz™): A New Melatonin Receptor Agonist for the Treatment of Non-24-Hour Sleep-Wake Disorder.
    Bonacci JM, Venci JV, Gandhi MA.
    J Pharm Pract; 2015 Oct 07; 28(5):473-8. PubMed ID: 25092604
    [Abstract] [Full Text] [Related]

  • 10. Caffeine does not entrain the circadian clock but improves daytime alertness in blind patients with non-24-hour rhythms.
    St Hilaire MA, Lockley SW.
    Sleep Med; 2015 Jun 07; 16(6):800-4. PubMed ID: 25891543
    [Abstract] [Full Text] [Related]

  • 11. Safety profile of tasimelteon, a melatonin MT1 and MT2 receptor agonist: pooled safety analyses from six clinical studies.
    Leger D, Quera-Salva MA, Vecchierini MF, Ogrizek P, Perry CA, Dressman MA.
    Expert Opin Drug Saf; 2015 Jun 07; 14(11):1673-85. PubMed ID: 26393492
    [Abstract] [Full Text] [Related]

  • 12. Tasimelteon, a melatonin agonist for the treatment of insomnia and circadian rhythm sleep disorders.
    Hardeland R.
    Curr Opin Investig Drugs; 2009 Jul 07; 10(7):691-701. PubMed ID: 19579175
    [Abstract] [Full Text] [Related]

  • 13. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
    Grainger JD, Locatelli F, Chotsampancharoen T, Donyush E, Pongtanakul B, Komvilaisak P, Sosothikul D, Drelichman G, Sirachainan N, Holzhauer S, Lebedev V, Lemons R, Pospisilova D, Ramenghi U, Bussel JB, Bakshi KK, Iyengar M, Chan GW, Chagin KD, Theodore D, Marcello LM, Bailey CK.
    Lancet; 2015 Oct 24; 386(10004):1649-58. PubMed ID: 26231455
    [Abstract] [Full Text] [Related]

  • 14. Tasimelteon (Hetlioz) for non-24-hour sleep-wake disorder.
    Med Lett Drugs Ther; 2014 Apr 28; 56(1441):34-5. PubMed ID: 24759294
    [No Abstract] [Full Text] [Related]

  • 15. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
    Bussel JB, de Miguel PG, Despotovic JM, Grainger JD, Sevilla J, Blanchette VS, Krishnamurti L, Connor P, David M, Boayue KB, Matthews DC, Lambert MP, Marcello LM, Iyengar M, Chan GW, Chagin KD, Theodore D, Bailey CK, Bakshi KK.
    Lancet Haematol; 2015 Aug 28; 2(8):e315-25. PubMed ID: 26688484
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
    Pivonello R, Fleseriu M, Newell-Price J, Bertagna X, Findling J, Shimatsu A, Gu F, Auchus R, Leelawattana R, Lee EJ, Kim JH, Lacroix A, Laplanche A, O'Connell P, Tauchmanova L, Pedroncelli AM, Biller BMK, LINC 3 investigators.
    Lancet Diabetes Endocrinol; 2020 Sep 28; 8(9):748-761. PubMed ID: 32730798
    [Abstract] [Full Text] [Related]

  • 17. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
    Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C.
    Lancet Oncol; 2012 Mar 28; 13(3):247-55. PubMed ID: 22341744
    [Abstract] [Full Text] [Related]

  • 18. Entrainment of free-running circadian rhythms by melatonin in blind people.
    Sack RL, Brandes RW, Kendall AR, Lewy AJ.
    N Engl J Med; 2000 Oct 12; 343(15):1070-7. PubMed ID: 11027741
    [Abstract] [Full Text] [Related]

  • 19. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
    Hurvitz SA, Andre F, Jiang Z, Shao Z, Mano MS, Neciosup SP, Tseng LM, Zhang Q, Shen K, Liu D, Dreosti LM, Burris HA, Toi M, Buyse ME, Cabaribere D, Lindsay MA, Rao S, Pacaud LB, Taran T, Slamon D.
    Lancet Oncol; 2015 Jul 12; 16(7):816-29. PubMed ID: 26092818
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study.
    Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS.
    Lancet Neurol; 2014 Sep 12; 13(9):885-92. PubMed ID: 25127173
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.